ClinicalTrials.gg
TerminatedNCT01602315Updated Dec 29, 2020Results posted

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 1/2 interventional study of BYL719 as film-coated (FC) whole tablets and BYL719 as dispersible tablets (DT) in Recurrent Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Squamous Cell Carcinoma, sponsored by Novartis Pharmaceuticals. Terminated at 29 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
early termination due to Sponsor decision (slow recruitment)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
179
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 19 under way, 7 of them phase 3. Cetuximab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
13th of 84
179 · median 46
Started
2012
with 3 others
Phase 1/2
8 of 86
none open now
Registered
43rd of 86
by date

Among the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, this one is the 13th largest by enrollment of the 84 interventional ones that give a count, is one of 4 that started in 2012, is one of 8 in phase 1/2, and was the 43rd registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This was a multi-center, open-label, Phase Ib dose escalation /Phase II study in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) patients considered to be resistant, ineligible or intolerant to platinum-based chemotherapy. The Phase Ib included three arms. Three different methods of administration and two different BYL719 formulations were studied to determine the MTD and/or RP2D of BYL719 in combination with cetuximab:

Arm A - film-coated whole tablets were orally administered to patients who were able to swallow the tablets; Arm B - a drinkable suspension prepared from crushed film-coated tablets was administered orally to patients with swallowing dysfunction Arm C - a suspension from a dispersible tablet administered via G-tube, in patients with swallowing dysfunction. Arm C was used to investigate the pharmacokinetics (PK), compared to Arm A (film coated tablet), and safety of the dispersible tablet of the dispersible tablet formulation of BYL719.

The Phase II investigated the clinical efficacy of BYL719 and consisted of an open label, randomized Phase II part investigating BYL719 in combination with cetuximab compared to cetuximab alone in patients resistant or intolerant to platinum and naïve to cetuximab (Scheme 1: Arm 1 and Arm 2), and a non-randomized Phase II part Scheme 2: Arm 3. In addition, patients who experienced disease progression in Arm 2 (cetuximab) were allowed to switch to the combination regimen (cross-over, Arm 2B). The safety of the BYL719 in combination with cetuximab was also further characterized in Arms 1, 2B and 3.

Patients were treated until progression of disease), unacceptable toxicity, or withdrawal of informed consent, whichever occurred first (except for phase II Arm 2 had the opportunity to crossover to the combination treatment (Arm 2B). In the follow-up period all patients had to complete the safety follow-up assessments within 30 days after the last dose of the study treatment. Patients who did not have disease progression at the time of discontinuation of study treatment were radiologically followed for disease status until disease progression, initiation of subsequent anticancer therapies, or death, whichever occurred first. In addition, all patients enrolled in Phase II were followed for survival.

03

Conditions studied

  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Metastatic Head and Neck Squamous Cell Carcinoma

Keywords

  • BYL719
  • PI3K inhibitor
  • PIK3CA
  • cetuximab
  • EGFR
  • HNSCC
  • RM HNSCC
  • platinum-based chemotherapy
  • (RM HNSCC) patients
  • resistant or ineligible/intolerant to platinum-based chemotherapy
  • swallowing dysfunction
  • G-tube
  • alpelisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients with histologically/-confirmed HNSCC
  • Patients must be resistant to platinum-based chemotherapy, or be ineligible (due to medical comorbidities) or intolerant to platinum-based therapy per medical history
  • For Phase Ib, there is no restriction on the number of prior therapies for recurrent or disease
  • For Phase II, patients may have received a maximum of 1 for recurrent or metastatic disease
  • For Phase Ib, prior cetuximab or other EGFR-targeted antibody therapy is allowed regardless of the prior treatment settings.
  • For Phase II, Arms 1 and 2, prior cetuximab or other EGFR-targeted antibody therapy is allowed only if administered in the induction setting, or concurrently with radiation in the curative setting, with the last dose of cetuximab administered at least 12 months prior to starting the study treatment. For Arm 3, prior cetuximab must have been administered in the curative, recurrent or metastatic disease setting and disease progression documented within 9 months of the last dose of cetuximab administered in that setting. This regimen (including both platinum and cetuximab) must be the most recent anti-neoplastic treatment regimen administered.
  • Patients with swallowing dysfunction who are unable to swallow BYL719 whole tablets and are not using feeding tubes for study drug administration can participate in the Phase Ib Arm B. For the Phase II, these patients with swallowing dysfunction may participate if able to drink the suspension and results of Arm B confirm the use of this method. Patients with swallowing dysfunction requiring G tube (G/PEG tube) for study drug administration may participate in Phase II if Arm C confirms dispersible tablet via G tube administration is permitted if the administration of drinkable suspension of BYL719 is allowed to be used in Phase II.
  • Availability of a representative tumor specimen. Patients enrolled in Arm 3 of Phase II must have disease sites amenable to unless prior agreement between Novartis and the Investigator.
  • At least one measurable or non- as per 1.1 criteria for patients in Phase Ib; Measurable disease as determined by RECIST v1.1 for Phase II patients
  • World Health Organization (WHO) Performance Status (PS) ≤ 2
  • Adequate organ function
  • Negative serum pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with PI3K-inhibitors
  • Patients with a prior serious infusion reaction to cetuximab
  • Patients with uncontrolled CNS tumor involvement
  • cardiac disease or impaired cardiac function
  • Patients with diabetes mellitus
  • Impaired GI function or GI disease
  • History of another within 2 years prior to starting study treatment
  • Pregnant or nursing (lactating) women
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
179 participants (actual)

Study arms

  • Experimental
    Phase Ib: A-BYL719 FC whole tab+cetux

    Oral film-coated tablets without swallowing dysfunction.

    Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab

  • Experimental
    Phase II: 2-Cetuximab

    Cetuximab in patients naive to cetuximab (phase ll)

    Biological: cetuximab

  • Experimental
    Phase Ib: B-BYL719 FC drink sus+cetux

    Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.

    Biological: cetuximab · Drug: BYL719 drink suspension

  • Experimental
    Phase II: 3-BYL719 + Cetuximab

    BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results

    Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab · Drug: BYL719 drink suspension

  • Experimental
    Phase II: 1-BYL719 + Cetuximab

    BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results

    Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab · Drug: BYL719 drink suspension

  • Experimental
    Phase Ib: C-BYL719 DT+cetux

    Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)

    Drug: BYL719 as dispersible tablets (DT) · Biological: cetuximab

  • Experimental
    Phase II: Cross over

    patients received BYL719 at RP2D in combination with cetuximab.

    Drug: BYL719 as film-coated (FC) whole tablets · Biological: cetuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ib Arms A: Probability That Dose Limiting Toxicities (DLTs) Rate is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)

    Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.

    Time frame: until disease progression or intolerable toxicity (approximately 6 months)

  2. Phase Ib Arm B: Probability That Distribution of Dose Limiting Toxicities (DLTs) is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)

    Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm B (crushed film-coated tablets as an oral suspension with swallowing dysfunction). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.

    Time frame: until disease progression or intolerable toxicity (approximately 6 months)

  3. For Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days)

    Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets) and arm B (BYL719 administered as a drinkable suspension in patients with swallowing dysfunction). 6 months is an approximate timeframe.

    Time frame: until disease progression or intolerable toxicity (approximately 6 months)

  4. Phase II Arms 1 and 2: Progression Free Survival (PFS) as Per RECIST v1.1 by Central Radiology Review

    Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab. 6 months is an approximate timeframe.

    Time frame: approximately 6 months

  5. Phase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.1

    Assessment of the anti-tumor activity of BYL719 in combination with cetuximab in patients resistant to platinum-based therapy and cetuximab.

    Time frame: approximately 6 months

  6. Phase Ib: Area Under Curve (AUC) 0-24 for BYL719 by Treatment

    Comparison of single-dose exposure of BYL719 dispersible tablet via G-tube in combination with cetuximab in RM HNSCC to that of Arm A (film-coated tables)

    Time frame: 6 months

Secondary outcomes

  1. Phase II: Progression Free Survival (PFS) as Per RECIST v 1.1

    Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab

    Time frame: approximately 6 months

  2. Phase Ib: Progression Free Survival (PFS) as Per RECIST v1.1

    Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C.

    Time frame: approximately 6 months

  3. Phase II: Randomized Best Overall Response as Per RECIST v1.1

    Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

    Time frame: approximately 6 months

  4. Phase II: Non-Randomized Best Overall Response as Per RECIST v1.1

    Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

    Time frame: approximately 6 months

  5. Phase II: Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

    Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arms 1 and 2.

    Time frame: approximately 6 months

  6. Phase II: Non-Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

    Scheme 1 (arm 3): Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm 3 (non-randomized arm)

    Time frame: approximately 6 months

  7. Phase II: Randomized Overall Survival (OS) by Treatment

    Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

    Time frame: approximately 1 year

  8. Phase II: Non-Randomized Overall Survival (OS) by Treatment

    Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

    Time frame: approximately 1 year

  9. For Phase Ib: Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

    Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C CR=complete response PR=partial response

    Time frame: approximately 6 months

  10. Phase II, Scheme 1 (Arm 2B): Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

    Phase II: Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab. Complete response (CR); Partial response (PR); Stable disease (SD)

    Time frame: Approximately 6 months

  11. Phase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over

    Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab.

    Time frame: approximately 1 year

  12. Phase Ib: Primary Plasma Pharmacokinetic Parameters for BYL719 by Treatment

    Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

    Time frame: 1 to 24 hours post dose (Day 1 Cycle 1)

  13. Phase Ib: Cmax for BYL719 by Treatment

    Non compartmental Cmax derived after single dose at Cycle 1 Day 1

    Time frame: Day 1 Cycle 1

  14. Phase Ib: Tmax for BYL719 by Treatment

    Non compartmental Cmax derived after single dose at Cycle 1 Day 1

    Time frame: Day 1 Cycle 1

  15. Phase Ib: Plasma Pharmacokinetic Parameters for BYL719 After Continuous Dose Administration (Steady State)

    Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

    Time frame: Day 1 Cycle 1

  16. Phase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State)

    Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

    Time frame: Day 1 Cycle 1

  17. Phase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State)

    Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

    Time frame: Day 1 Cycle 1

  18. Phase Ib: Notable Abnormal Vital Signs by Treatment

    Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.

    Time frame: approximately 6 months

  19. Phase Ib: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities

    Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.

    Time frame: baseline, post baseline

  20. For Phase II: Notable Abnormal Vital Signs by Treatment

    Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.

    Time frame: approximately 6 months

  21. For Phase II: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities

    Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.

    Time frame: baseline, post baseline during the entire study period (approximately 1 year)

  22. Phase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment

    Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

    Time frame: approximately 6 months

07

Results

Posted May 21, 2018
Limitations and caveats
Recruitment of new patients who were resistant to both platinum \& cetuximab into Arm 3 was halted due to slow enrollment. The study was terminated early and health authorities were informed.

Participant flow

45 patients enrolled in Phase Ib, 106 cetuximab naïve patients in Phase II were randomized to either BYL719+cet (N=71) or cet monotherapy (N=35). Of the 35 patients, 16 crossed over to BYL719+cet combo treatment. 29 patients enrolled in the non-randomized combo treatment arm (cet resistant patients). All patients have completed the trial.

Participant flow — Overall Study
MilestoneArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible TabletsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 3 - BYL719+Cetuximab (Non-randomized)
Started165186713529
Completed0000000
Not completed165186713529
Withdrew: Protocol violation0000010
Withdrew: Physician decision2000211
Withdrew: Disease progression63101411215
Withdrew: Death1111722
Withdrew: Withdrawal by subject2020601
Withdrew: Adverse event51541539
Withdrew: Subject/guardian decision0000001
Withdrew: Cross-over patients to combo treatment00000160

Outcome measures

PrimaryPhase Ib Arms A: Probability That Dose Limiting Toxicities (DLTs) Rate is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)

Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.

Time frame:
until disease progression or intolerable toxicity (approximately 6 months)
Reported as:
Number · Probability of DLT rate
Phase Ib Arms A: Probability That Dose Limiting Toxicities (DLTs) Rate is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)
Probability of DLT rateArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+Cetuximab
Posterior probabilities that Pr(DLT) in 0-0.160.7640.086
Posterior probabilities that Pr (DLT) in 0.16-0.350.2220.376
Posterior probabilities that Pr (DLT) in 0.35-10.0150.538
PrimaryPhase Ib Arm B: Probability That Distribution of Dose Limiting Toxicities (DLTs) is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)

Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm B (crushed film-coated tablets as an oral suspension with swallowing dysfunction). Dose recommendation was based on posterior summaries including the mean, median, standard deviation, 95%-credibility interval, and the probability that the true DLT rate for each dose combination lies in one of the following categories: (0%, 16%) under-dosing; (16%, 35%) targeted toxicity; (35%, 100%) excessive toxicity. The combination treatment was considered superior to cetuximab alone if the posterior probability (HR \> 1) \< 10%, and the posterior median HR \< 0.7.

Time frame:
until disease progression or intolerable toxicity (approximately 6 months)
Reported as:
Number · Probability of DLT rate
Phase Ib Arm B: Probability That Distribution of Dose Limiting Toxicities (DLTs) is in the Recommended Phase 2 Dose in Cycle 1 (Cycle 1=28 Days)
Probability of DLT rateArm B- 300mg BYL719+Cetuximab
Posterior probabilities that Pr(DLT) in 0-0.160.267
Posterior probabilities that Pr (DLT) in 0.16-0.350.664
Posterior probabilities that Pr (DLT) in 0.35-10.069
PrimaryFor Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days)

Estimation of Maximum Tolerated Doses (MTDs) and/or recommended Phase II doses (RP2Ds) of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC) in arm A (BYL719 administered as a whole tablet in patients able to swallow the tablets) and arm B (BYL719 administered as a drinkable suspension in patients with swallowing dysfunction). 6 months is an approximate timeframe.

Time frame:
until disease progression or intolerable toxicity (approximately 6 months)
Reported as:
Number · Participants
For Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days)
ParticipantsArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible TabletsAll Patients
For Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 Days)12429
PrimaryPhase II Arms 1 and 2: Progression Free Survival (PFS) as Per RECIST v1.1 by Central Radiology Review

Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab. 6 months is an approximate timeframe.

Time frame:
approximately 6 months
Reported as:
Number · participants
Phase II Arms 1 and 2: Progression Free Survival (PFS) as Per RECIST v1.1 by Central Radiology Review
participantsBYL719+ Cetuximab (Randomized)Monotherapy Cetuximab (Randomized)
Number of PFS events46 (0.643 to 1.529)27
Progression3325
Number of censored258
Death132
Statistical analysis
  • BYL719+ Cetuximab (Randomized) vs Monotherapy Cetuximab (Randomized) · Median hr: 0.990
  • BYL719+ Cetuximab (Randomized) vs Monotherapy Cetuximab (Randomized) · Regression, Cox · p = 0.643 · Hazard ratio (hr): 1.12 · 95% CI 0.69 to 1.82
  • BYL719+ Cetuximab (Randomized) vs Monotherapy Cetuximab (Randomized) · Regression, Cox · p = 0.039 · Hazard ratio (hr): 0.54 · 95% CI 0.30 to 0.97
PrimaryPhase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.1

Assessment of the anti-tumor activity of BYL719 in combination with cetuximab in patients resistant to platinum-based therapy and cetuximab.

Time frame:
approximately 6 months
Reported as:
Median · months
Phase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.1
monthsBYL719+ Cetuximab (Non-randomized)
Phase II Arm 3: Progression Free Survival (PFS) as Per RECIST V1.13.896 (2.868 to 5.241)
PrimaryPhase Ib: Area Under Curve (AUC) 0-24 for BYL719 by Treatment

Comparison of single-dose exposure of BYL719 dispersible tablet via G-tube in combination with cetuximab in RM HNSCC to that of Arm A (film-coated tables)

Time frame:
6 months
Reported as:
Median · hr*ng/mL
Phase Ib: Area Under Curve (AUC) 0-24 for BYL719 by Treatment
hr*ng/mLArm A - 300mg BYL719+CetuximabArm C: BYL719+Cetixumab, Dispersible TabletsArm A: 400mg BYL719 + CetuximabArm B: 300mg BYL719 + Cetuximab
AUCinf22600 (16600 to 48500)24100 (9290 to 33200)27800 (17200 to 60100)27300 (15700 to 47400)
AUC0_2418800 (5590 to 43400)19400 (7580 to 32100)26300 (16000 to 56100)25600 (14600 to 42100)
AUClast19200 (5830 to 42700)22100 (4390 to 31800)26200 (15800 to 55600)25000 (14400 to 41900)
SecondaryPhase II: Progression Free Survival (PFS) as Per RECIST v 1.1

Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab

Time frame:
approximately 6 months
Reported as:
Number · Participants
Phase II: Progression Free Survival (PFS) as Per RECIST v 1.1
ParticipantsArm 2B - BYL719+Cetuximab
Number of PFS12
Progression9
Death3
Number of Censored4
Statistical analysis
  • Arm 2B - BYL719+Cetuximab · Kaplan-meier method (median): 43.0 · 95% CI 27.0 to 88.0days
SecondaryPhase Ib: Progression Free Survival (PFS) as Per RECIST v1.1

Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C.

Time frame:
approximately 6 months
Reported as:
Number · Participants
Phase Ib: Progression Free Survival (PFS) as Per RECIST v1.1
ParticipantsArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible Tablets
PFS event (Progression)52102
PFS event (Death)2211
Number of Censored9173
SecondaryPhase II: Randomized Best Overall Response as Per RECIST v1.1

Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

Time frame:
approximately 6 months
Reported as:
Number · Participants
Phase II: Randomized Best Overall Response as Per RECIST v1.1
ParticipantsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)All Patients
Complete Response101
Partial Response628
Stable Disease24832
Progressive Disease171229
Non-CR/Non-PD (NCRNPD)61016
Unknown17320
SecondaryPhase II: Non-Randomized Best Overall Response as Per RECIST v1.1

Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

Time frame:
approximately 6 months
Reported as:
Number · Participants
Phase II: Non-Randomized Best Overall Response as Per RECIST v1.1
ParticipantsArm 3 - BYL719+Cetuximab
Complete Response (CR)1
Partial Response (PR)2
Stable Disease (SD)8
Progressive Disease (PD)5
Non-CR/Non-PD (NCRNPD)6
Unknown7
SecondaryPhase II: Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arms 1 and 2.

Time frame:
approximately 6 months
Reported as:
Number · Percentages
Phase II: Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
PercentagesArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)All Patients (Phase II)
Overall response rate (ORR) (CR or PR)9.9 (4.1 to 19.3)5.7 (0.7 to 19.2)8.5 (4.0 to 15.5)
Disease control rate 1 (DCR 1) (CR or PR or SD)43.7 (31.9 to 56.0)28.6 (14.6 to 46.3)38.7 (29.4 to 48.6)
DCR 2 (CR or PR or SD or Non-CR/Non-PD)52.1 (39.9 to 64.1)57.1 (39.4 to 73.7)53.8 (43.8 to 63.5)
SecondaryPhase II: Non-Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

Scheme 1 (arm 3): Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm 3 (non-randomized arm)

Time frame:
approximately 6 months
Reported as:
Number · Percentages
Phase II: Non-Randomized Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
PercentagesArm 3 - BYL719+Cetuximab
Overall response rate (ORR) (CR or PR)10.3 (2.2 to 27.4)
Disease control rate 1 (DCR 1) (CR or PR or SD)37.9 (20.7 to 57.7)
DCR 2 (CR or PR or SD or Non-CR/Non-PD)58.6 (38.9 to 76.5)
SecondaryPhase II: Randomized Overall Survival (OS) by Treatment

Scheme 1 (Arms 1 and 2): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

Time frame:
approximately 1 year
Reported as:
Number · Patients
Phase II: Randomized Overall Survival (OS) by Treatment
PatientsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)
Number of deaths5126
Number of censored209
Statistical analysis
  • Arm 1 - BYL719+Cetuximab (Randomized) vs Arm 2 - Monotherapy Cetuximab (Randomized) · Regression, Cox · p = 0.313 · Hazard ratio (hr): 1.28 · 95% CI 0.79 to 2.05
SecondaryPhase II: Non-Randomized Overall Survival (OS) by Treatment

Scheme 1 (Arm 3): Further assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

Time frame:
approximately 1 year
Reported as:
Number · Patients
Phase II: Non-Randomized Overall Survival (OS) by Treatment
PatientsArm 3 - BYL719+Cetuximab
Number of deaths13
Number of censored10
Statistical analysis
  • Arm 3 - BYL719+Cetuximab · Kaplan-meier (median): 294.0 · 95% CI 172.0 to 463.0
SecondaryFor Phase Ib: Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

Assessment of the preliminary anti-tumor activity of BYL719 in combination with cetuximab in arm A, B and C CR=complete response PR=partial response

Time frame:
approximately 6 months
Reported as:
Number · Percentages
For Phase Ib: Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
PercentagesArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible TabletsAll Patients
ORR (CR) or PR)25.5 (7.3 to 52.4)0.0 (0.0 to 52.2)0.0 (0.0 to 18.5)0.0 (0.0 to 45.9)8.9 (2.5 to 21.2)
DCR (CR or PR or Stable Disease or non-CR/Non-PD)75.0 (47.6 to 92.7)20.0 (0.5 to 71.6)50.0 (26.0 to 74.0)16.7 (0.4 to 64.1)51.1 (35.8 to 66.3)
SecondaryPhase II, Scheme 1 (Arm 2B): Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1

Phase II: Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab. Complete response (CR); Partial response (PR); Stable disease (SD)

Time frame:
Approximately 6 months
Reported as:
Number · Rate
Phase II, Scheme 1 (Arm 2B): Overall Response Rate (ORR) and Disease Control Rate (DCR) as Per RECIST v1.1
RateArm 2B - BYL719+Cetuximab
Overall Response (ORR) - CR or PR0 (NA to NA)
Disease Control Rate (DCR) - CR, PR, or SD25.0 (7.27 to 52.38)
SecondaryPhase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over

Phase II, Scheme 1 (Arm 2B): To further assess the anti-tumor activity of BYL719 + cetuximab in the setting of resistance to single agent cetuximab.

Time frame:
approximately 1 year
Reported as:
Median · Days
Phase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over
DaysArm 2B - BYL719+Cetuximab
Phase II, Scheme 2 (Arm 2B): Overall Survival (OS) for the Cross-over96.0 (87.0 to 148.0)
SecondaryPhase Ib: Primary Plasma Pharmacokinetic Parameters for BYL719 by Treatment

Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

Time frame:
1 to 24 hours post dose (Day 1 Cycle 1)
Reported as:
Median · hr*ng/mL
Phase Ib: Primary Plasma Pharmacokinetic Parameters for BYL719 by Treatment
hr*ng/mLArm A - 300mg BYL719+CetuximabArm B: BYL719 + Cetuximab, Oral SuspensionArm C: BYL719+Cetixumab, Dispersible TabletsArm A: 400mg BYL719 + Cetuximab
AUCinf22600 (16600 to 48500)27300 (15700 to 47400)24100 (9290 to 33200)27800 (17200 to 60100)
AUC0_2418800 (5590 to 43400)25600 (14600 to 42100)19400 (7580 to 32100)26300 (16000 to 56100)
AUClast19200 (5830 to 42700)2370 (1330 to 3710)22100 (4390 to 31800)26200 (15800 to 55600)
SecondaryPhase Ib: Cmax for BYL719 by Treatment

Non compartmental Cmax derived after single dose at Cycle 1 Day 1

Time frame:
Day 1 Cycle 1
Reported as:
Median · ng/mL
Phase Ib: Cmax for BYL719 by Treatment
ng/mLArm A - 300mg BYL719+CetuximabArm B: BYL719 + Cetuximab, Oral SuspensionArm C: BYL719+Cetixumab, Dispersible TabletsArm A: 400mg BYL719 + Cetuximab
Phase Ib: Cmax for BYL719 by Treatment2130 (303 to 4280)2370 (1330 to 3710)2010 (682 to 2980)2520 (1800 to 6240)
SecondaryPhase Ib: Tmax for BYL719 by Treatment

Non compartmental Cmax derived after single dose at Cycle 1 Day 1

Time frame:
Day 1 Cycle 1
Reported as:
Median · hr
Phase Ib: Tmax for BYL719 by Treatment
hrArm A - 300mg BYL719+CetuximabArm B: BYL719 + Cetuximab, Oral SuspensionArm C: BYL719+Cetixumab, Dispersible TabletsArm A: 400mg BYL719 + Cetuximab
Phase Ib: Tmax for BYL719 by Treatment2.02 (1 to 24.8)2.97 (1 to 5.87)3 (0.767 to 6)2.23 (1.58 to 3.02)
SecondaryPhase Ib: Plasma Pharmacokinetic Parameters for BYL719 After Continuous Dose Administration (Steady State)

Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

Time frame:
Day 1 Cycle 1
Reported as:
Median · hr*ng/mL
Phase Ib: Plasma Pharmacokinetic Parameters for BYL719 After Continuous Dose Administration (Steady State)
hr*ng/mLArm A - 300mg BYL719+CetuximabArm B: BYL719 + Cetuximab, Oral SuspensionArm C: BYL719+Cetixumab, Dispersible Tablets
AUC (0-24)24600 (17900 to 44400)28500 (12700 to 53900)30500 (30500 to 30500)
AUClast24500 (18000 to 76100)2370 (1330 to 3710)22100 (4390 to 31800)
SecondaryPhase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State)

Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

Time frame:
Day 1 Cycle 1
Reported as:
Median · ng/mL
Phase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State)
ng/mLArm A - 300mg BYL719+CetuximabArm B: BYL719 + Cetuximab, Oral SuspensionArm C: BYL719+Cetixumab, Dispersible Tablets
Phase Ib: Cmax for BYL719 After Continuous Dose Administration (Steady State)2200 (1710 to 6520)2820 (373 to 4710)2750 (2750 to 2750)
SecondaryPhase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State)

Non compartmental PK parameters derived after single dose at Cycle 1 Day 1

Time frame:
Day 1 Cycle 1
Reported as:
Median · hr
Phase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State)
hrArm A - 300mg BYL719+CetuximabArm B: BYL719 + Cetuximab, Oral SuspensionArm C: BYL719+Cetixumab, Dispersible Tablets
Phase Ib: Tmax for BYL719 After Continuous Dose Administration (Steady State)3.15 (1.5 to 7.13)3.15 (1.03 to 8)1 (1 to 1)
SecondaryPhase Ib: Notable Abnormal Vital Signs by Treatment

Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.

Time frame:
approximately 6 months
Reported as:
Number · Participants
Phase Ib: Notable Abnormal Vital Signs by Treatment
ParticipantsArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible Tablets
Sitting Pulse rate (bpm): High only0044
Sitting Pulse rate (bpm): Low only0000
Sitting Pulse rate (bpm): High and low0000
Sitting systolic B.P. (mmHg): High only1010
Sitting systolic B.P. (mmHg): Low only1001
Sitting systolic B.P. (mmHg): High and low0010
Sitting diastolic B.P. (mmHg): High only0010
Sitting diastolic B.P. (mmHg): Low only1020
Sitting diastolic B.P. (mmHg): High and low0000
Body Temperature (Celsius): High only0001
Body Temperature (Celsius): Low only0000
Body Temperature (Celsius): High and low0000
Weight (kg): High only0000
Weight (kg): Low only7133
Weight (kg): High and low0000
Respiratory Rate (bpm): High only0021
Respiratory Rate (bpm): Low only0000
Respiratory Rate (bpm): High and low0000
SecondaryPhase Ib: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities

Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm A, B and C.

Time frame:
baseline, post baseline
Reported as:
Number · Participants
Phase Ib: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities
ParticipantsArm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible Tablets
QTcF (msec): Increase from baseline > 3094101
QTcF (msec): Increase from baseline > 602010
QTcB (msec): Increase from baseline > 30114121
QTcB (msec): Increase from baseline > 601011
QT (msec): Increase from baseline > 3014101
QT (msec): Increase from baseline > 604030
VR (bpm): RR decrease > 25% & to a VR > 1000111
VR (bpm): RR decrease > 25% & to a VR < 500000
PR (msec): increase > 25% & to a VR > 2000000
QRS (msec): increase > 25% & to a VR > 1100000
SecondaryFor Phase II: Notable Abnormal Vital Signs by Treatment

Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.

Time frame:
approximately 6 months
Reported as:
Number · Participants
For Phase II: Notable Abnormal Vital Signs by Treatment
ParticipantsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 2B - BYL719+Cetuximab
Sitting Pulse rate (bpm): High only435
Sitting Pulse rate (bpm): Low only101
Sitting Pulse rate (bpm): High and low000
Sitting systolic B.P. (mmHg): High only010
Sitting systolic B.P. (mmHg): Low only1131
Sitting systolic B.P. (mmHg): High and low100
Sitting diastolic B.P. (mmHg): High only120
Sitting diastolic B.P. (mmHg): Low only432
Sitting diastolic B.P. (mmHg): High and low100
Body Temperature (Celsius): High only100
Body Temperature (Celsius): Low only312
Body Temperature (Celsius): High and low000
Weight (kg): High only140
Weight (kg): Low only3139
Weight (kg): High and low000
Respiratory Rate (bpm): High only201
Respiratory Rate (bpm): Low only214
Respiratory Rate (bpm): High and low000
SecondaryFor Phase II: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities

Characterization of the safety and tolerability of BYL719 in combination with cetuximab in arm 1, 2 and 2B.

Time frame:
baseline, post baseline during the entire study period (approximately 1 year)
Reported as:
Number · Participants
For Phase II: Number of Patients With Notable Electrocardiogram (ECG) Abnormalities
ParticipantsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 2B - BYL719+Cetuximab
QTcF (msec): Increase from baseline > 3035415
QTcF (msec): Increase from baseline > 60612
QTcB (msec): Increase from baseline > 30401215
QTcB (msec): Increase from baseline > 60702
QT (msec): Increase from baseline > 30431323
QT (msec): Increase from baseline > 601725
VR (bpm): RR decrease > 25% & to a VR > 100943
VR (bpm): RR decrease > 25% & to a VR < 50100
PR (msec): increase > 25% & to a VR > 200000
QRS (msec): increase > 25% & to a VR > 110001
SecondaryPhase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment

Assessment of the anti-tumor activity of BYL719 in combination with cetuximab vs. cetuximab as single-agent in RM HNSCC patients naive to cetuximab

Time frame:
approximately 6 months
Reported as:
Median · Days
Phase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment
DaysBYL719+ Cetuximab (Randomized)Monotherapy Cetuximab (Randomized)BYL719=Cetuximab (Non-randomized)
Phase II: Progression Free Survival (PFS) Based on Investigator's Assessment With Treatment94.0 (58.0 to 135.0)85.0 (49.0 to 127.0)117.0 (50.0 to 184.0)
Statistical analysis
  • BYL719+ Cetuximab (Randomized) vs Monotherapy Cetuximab (Randomized) · Regression, Cox · p = 0.235 · Hazard ratio (hr): 0.76 · 95% CI 0.49 to 1.19
  • BYL719+ Cetuximab (Randomized) vs Monotherapy Cetuximab (Randomized) · Regression, Cox · p = 0.062 · Hazard ratio (hr): 0.64 · 95% CI 0.4 to 1.02

Adverse events

Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse Events reported in this record are from date of First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - 300mg BYL719+Cetuximab—9/15 (60%)15/15 (100%)
Arm A: 400 mg BYL719 + Cetuximab—4/5 (80%)5/5 (100%)
Arm B - BYL719 + Cetuximab Oral Suspension—12/18 (66.7%)18/18 (100%)
Arm C - BYL719+Cetuximab Dispersible Tablets—4/6 (66.7%)6/6 (100%)
Arm 1 - BYL719+Cetuximab (Randomized)—40/69 (58%)69/69 (100%)
Arm 2 - Monotherapy Cetuximab (Randomized)—15/35 (42.9%)35/35 (100%)
Arm 3 - BYL719+Cetuximab (Non-randomized)—15/29 (51.7%)29/29 (100%)
All Patients—99/178 (55.6%)177/178 (99.4%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventArm A - 300mg BYL719+CetuximabArm A: 400 mg BYL719 + CetuximabArm B - BYL719 + Cetuximab Oral SuspensionArm C - BYL719+Cetuximab Dispersible TabletsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 3 - BYL719+Cetuximab (Non-randomized)All Patients
HyperglycaemiaMetabolism and nutrition disorders1/150/50/182/67/690/355/2915/178
PneumoniaInfections and infestations2/150/54/181/68/691/354/2920/178
Myocardial ischaemiaCardiac disorders0/151/50/180/60/690/350/291/178
Oesophageal ulcerGastrointestinal disorders0/151/50/180/60/690/350/291/178
Tumour lysis syndromeMetabolism and nutrition disorders0/151/50/180/60/690/350/291/178
Muscular weaknessMusculoskeletal and connective tissue disorders0/151/50/180/63/690/350/294/178
Device dislocationProduct Issues0/151/50/180/60/690/350/291/178
DyspnoeaRespiratory, thoracic and mediastinal disorders0/151/50/180/63/691/351/296/178
Atrial fibrillationCardiac disorders0/150/50/181/61/690/350/292/178
PyrexiaGeneral disorders1/150/51/181/64/691/350/298/178
Most frequent other events
Showing 10 of 227
Most frequent other events
EventArm A - 300mg BYL719+CetuximabArm A: 400 mg BYL719 + CetuximabArm B - BYL719 + Cetuximab Oral SuspensionArm C - BYL719+Cetuximab Dispersible TabletsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 3 - BYL719+Cetuximab (Non-randomized)All Patients
HyperglycaemiaMetabolism and nutrition disorders8/152/510/185/642/695/3516/2988/178
DiarrhoeaGastrointestinal disorders7/152/510/182/629/695/3513/2968/178
HypomagnesaemiaMetabolism and nutrition disorders8/152/56/181/618/698/3512/2955/178
ConstipationGastrointestinal disorders2/150/54/183/69/697/355/2930/178
Weight decreasedInvestigations6/152/56/183/627/697/3511/2962/178
DehydrationMetabolism and nutrition disorders0/151/50/183/65/691/353/2913/178
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/151/51/183/64/692/352/2913/178
FatigueGeneral disorders5/152/55/180/622/698/3514/2956/178
StomatitisGastrointestinal disorders7/152/58/181/631/696/3512/2967/178
Dermatitis acneiformSkin and subcutaneous tissue disorders7/152/54/180/621/698/355/2947/178

Baseline characteristics

Full Analysis Set (FAS) consisted of all patients who received at least one dose of either BYL719 or Cetuximab in Phase Ib and Phase II Arm 3, and all randomized patients in Phase II Scheme 1, Arm 1 and Arm 2.

Age, Continuous
Age, Continuous(years)Arm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible TabletsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 3 - BYL719+Cetuximab (Non-randomized)Total
Mean52.8 ± 13.4062.6 ± 7.9956.7 ± 10.2060.5 ± 14.1057.2 ± 9.6657.1 ± 10.3756.9 ± 8.2557.0 ± 10.16
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - 300mg BYL719+CetuximabArm A - 400mg BYL719+CetuximabArm B - BYL719 + Cetuximab, Oral SuspensionArm C - BYL719+Cetuximab, Dispersible TabletsArm 1 - BYL719+Cetuximab (Randomized)Arm 2 - Monotherapy Cetuximab (Randomized)Arm 3 - BYL719+Cetuximab (Non-randomized)Total
Female71421641044
Male94144553119136
08

Study locations

29 sites
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    San Francisco, California 94101, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Jacksonville, Florida 32224, United States
  • Novartis Investigative Site
    Orlando, Florida 32806, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30322, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02114, United States
  • Novartis Investigative Site
    Saint Louis, Missouri 63110, United States
  • Novartis Investigative Site
    New York, New York 10017, United States
  • Novartis Investigative Site
    New York, New York 10029, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29425, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37232, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Murdoch, Western Australia 6150, Australia
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Lyon Cedex, 69373, France
  • Novartis Investigative Site
    Toulouse Cedex 9, 31059, France
  • Novartis Investigative Site
    Shatin, New Territories, Hong Kong
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 06351, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Maastricht, 5800, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6500 HB, Netherlands
  • Novartis Investigative Site
    Singapore, 169610, Singapore
  • Novartis Investigative Site
    Tainan, Taiwan ROC 70421, Taiwan
  • Novartis Investigative Site
    Kuei-Shan Chiang, Taoyuan/ Taiwan ROC 33305, Taiwan
  • Novartis Investigative Site
    Taipei, 10048, Taiwan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Sep 2016, 46 months.

Results were first posted in May 2018, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2012
First posted
May 18, 2012
StartActual
Nov 12, 2012
Primary completionActual
Sep 16, 2016
CompletionActual
Sep 16, 2016
Results first posted
May 21, 2018
Last update
Dec 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01602315
Responsible party
Sponsor
First posted
May 18, 2012
Start date
Nov 12, 2012
Primary completion
Sep 16, 2016
Completion
Sep 16, 2016
Results posted
May 21, 2018
Last update
Dec 29, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Cetuximab

Start the discussion